Experimental animal models in the study of GVL reactions

Robert L. Truitt, Bryon D. Johnson, Robert Korngold, Robert Townsend, Bruce R Blazar

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The hypothesis that bone marrow transplantation (BMT) can provide an effective antileukemia reaction was tested in experimental models during the very earliest days of BMT research. Barnes and coworkers [1], in their 1956 paper entitled Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow, described the potential and problems of using allogeneic BMT for the treatment of leukemia in this way: When mice are given an otherwise lethal dose of x rays to the whole body they can recover if injected intravenously with homologous [allogeneic] myeloid cells…. This suggests that leukemia of the mouse might be successfully treated. On the one hand, the dose of x rays which is sufficiently lethal to normal cells of the bone marrow and lymphatic tissues to cause death of the animal might well be completely lethal to leukemic cells…. On the other hand, if the dose of x rays sufficient to kill the animal is not 100% lethal to leukemic cells, the malignant condition would in these circumstances recur by growth from the surviving cells, since neither host not graft has the ability to resist; but, if homologous bone marrow from a different strain of mouse were given, the colonizing cells might retain the capacity of the donor to destroy by the reaction of immunity these residual leukemic cells-and perhaps also the host.

Original languageEnglish (US)
Title of host publicationAllogeneic Immunotherapy for Malignant Diseases
PublisherCRC Press
Pages39-74
Number of pages36
ISBN (Electronic)9780203909508
ISBN (Print)9780824767815
StatePublished - Jan 1 2000

Fingerprint

Animal Models
Bone Marrow Transplantation
X-Rays
Leukemia
Bone Marrow
Homologous Transplantation
Lymphoid Tissue
Myeloid Cells
Cause of Death
Immunity
Theoretical Models
Transplants
Bone and Bones
Therapeutics
Growth
Research

Cite this

Truitt, R. L., Johnson, B. D., Korngold, R., Townsend, R., & Blazar, B. R. (2000). Experimental animal models in the study of GVL reactions. In Allogeneic Immunotherapy for Malignant Diseases (pp. 39-74). CRC Press.

Experimental animal models in the study of GVL reactions. / Truitt, Robert L.; Johnson, Bryon D.; Korngold, Robert; Townsend, Robert; Blazar, Bruce R.

Allogeneic Immunotherapy for Malignant Diseases. CRC Press, 2000. p. 39-74.

Research output: Chapter in Book/Report/Conference proceedingChapter

Truitt, RL, Johnson, BD, Korngold, R, Townsend, R & Blazar, BR 2000, Experimental animal models in the study of GVL reactions. in Allogeneic Immunotherapy for Malignant Diseases. CRC Press, pp. 39-74.
Truitt RL, Johnson BD, Korngold R, Townsend R, Blazar BR. Experimental animal models in the study of GVL reactions. In Allogeneic Immunotherapy for Malignant Diseases. CRC Press. 2000. p. 39-74
Truitt, Robert L. ; Johnson, Bryon D. ; Korngold, Robert ; Townsend, Robert ; Blazar, Bruce R. / Experimental animal models in the study of GVL reactions. Allogeneic Immunotherapy for Malignant Diseases. CRC Press, 2000. pp. 39-74
@inbook{aa243c97937843cc8b804f9d78c04833,
title = "Experimental animal models in the study of GVL reactions",
abstract = "The hypothesis that bone marrow transplantation (BMT) can provide an effective antileukemia reaction was tested in experimental models during the very earliest days of BMT research. Barnes and coworkers [1], in their 1956 paper entitled Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow, described the potential and problems of using allogeneic BMT for the treatment of leukemia in this way: When mice are given an otherwise lethal dose of x rays to the whole body they can recover if injected intravenously with homologous [allogeneic] myeloid cells…. This suggests that leukemia of the mouse might be successfully treated. On the one hand, the dose of x rays which is sufficiently lethal to normal cells of the bone marrow and lymphatic tissues to cause death of the animal might well be completely lethal to leukemic cells…. On the other hand, if the dose of x rays sufficient to kill the animal is not 100{\%} lethal to leukemic cells, the malignant condition would in these circumstances recur by growth from the surviving cells, since neither host not graft has the ability to resist; but, if homologous bone marrow from a different strain of mouse were given, the colonizing cells might retain the capacity of the donor to destroy by the reaction of immunity these residual leukemic cells-and perhaps also the host.",
author = "Truitt, {Robert L.} and Johnson, {Bryon D.} and Robert Korngold and Robert Townsend and Blazar, {Bruce R}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824767815",
pages = "39--74",
booktitle = "Allogeneic Immunotherapy for Malignant Diseases",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - Experimental animal models in the study of GVL reactions

AU - Truitt, Robert L.

AU - Johnson, Bryon D.

AU - Korngold, Robert

AU - Townsend, Robert

AU - Blazar, Bruce R

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The hypothesis that bone marrow transplantation (BMT) can provide an effective antileukemia reaction was tested in experimental models during the very earliest days of BMT research. Barnes and coworkers [1], in their 1956 paper entitled Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow, described the potential and problems of using allogeneic BMT for the treatment of leukemia in this way: When mice are given an otherwise lethal dose of x rays to the whole body they can recover if injected intravenously with homologous [allogeneic] myeloid cells…. This suggests that leukemia of the mouse might be successfully treated. On the one hand, the dose of x rays which is sufficiently lethal to normal cells of the bone marrow and lymphatic tissues to cause death of the animal might well be completely lethal to leukemic cells…. On the other hand, if the dose of x rays sufficient to kill the animal is not 100% lethal to leukemic cells, the malignant condition would in these circumstances recur by growth from the surviving cells, since neither host not graft has the ability to resist; but, if homologous bone marrow from a different strain of mouse were given, the colonizing cells might retain the capacity of the donor to destroy by the reaction of immunity these residual leukemic cells-and perhaps also the host.

AB - The hypothesis that bone marrow transplantation (BMT) can provide an effective antileukemia reaction was tested in experimental models during the very earliest days of BMT research. Barnes and coworkers [1], in their 1956 paper entitled Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow, described the potential and problems of using allogeneic BMT for the treatment of leukemia in this way: When mice are given an otherwise lethal dose of x rays to the whole body they can recover if injected intravenously with homologous [allogeneic] myeloid cells…. This suggests that leukemia of the mouse might be successfully treated. On the one hand, the dose of x rays which is sufficiently lethal to normal cells of the bone marrow and lymphatic tissues to cause death of the animal might well be completely lethal to leukemic cells…. On the other hand, if the dose of x rays sufficient to kill the animal is not 100% lethal to leukemic cells, the malignant condition would in these circumstances recur by growth from the surviving cells, since neither host not graft has the ability to resist; but, if homologous bone marrow from a different strain of mouse were given, the colonizing cells might retain the capacity of the donor to destroy by the reaction of immunity these residual leukemic cells-and perhaps also the host.

UR - http://www.scopus.com/inward/record.url?scp=0006857807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0006857807&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0006857807

SN - 9780824767815

SP - 39

EP - 74

BT - Allogeneic Immunotherapy for Malignant Diseases

PB - CRC Press

ER -